Acumen Pharmaceuticals公布了2025年第四季度财报,净亏损1.213亿美元,主要由于与ALTITUDE-AD临床试验相关的研发费用增加所致。该公司强调其现金状况稳健,达到1.169亿美元,这得益于最近完成的3575万美元私募融资。在盘前交易中,Acumen股价下跌3.38%至2.541美元,反映出尽管其阿尔茨海默病治疗管线取得战略进展,投资者仍持谨慎态度。

美国国立卫生研究院化学基因组中心（NCGC）的常规工作之一是进行自动化的高内涵高通量筛选。那么，你一定想知道，这个经济实力雄厚、研究成果斐然、人才济济、设备先进的顶级研究院选择了怎样的平台？如何进行这种艰苦而乏味的工作呢？那就跟着生物通 ...

The current quarter featured the announcement of a $35.75 million private placement to support EBD program development and a clear target for an IND filing in mid-2027.

Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Is Acumen Pharmaceuticals, Inc. (ABOS) one of those stocks right now? Let's take a ...

生物通首页 > 今日动态> 专题总汇> 高内涵筛选的利器——Acumen e X3 前言：高内涵筛选通常离不开微孔板。微孔板读数仪经过不断演化，已经从检测每个孔平均信号的光电倍增管进化到了解单细胞特征的显微镜样成像系统。然而，目前的微孔板读数仪在读板速度和 ...

Acumen是一家生物制药商，正致力于开发一种靶向免疫治疗候选药物ACU193，并在早期AD患者中建立机制证明。ACU193是一种人源化单克隆抗体，选择性靶向a ß os，已在体外试验中证明了功能和保护作用，并在包括AD转基因模型在内的多个动物物种中证明了体内安全性和药理活性。我们于2021年第二季度启动了ACU193的1期临床试验，目的是评估其安全性和耐受性，并探索其药代动力学和靶点参与。近日， ...

Acumen Pharmaceuticals is a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AßOs) for the treatment of Alzheimer’s disease ...

CEO Dan O'Connell reported that Acumen completed enrollment of its 542-participant Phase 2 ALTITUDE-AD study evaluating Sabirnetug for early Alzheimer’s disease, stating, "We completed enrollment of ...

Julie Brush, Solutus founding partner. Once upon a time, there was a lawyer. She was a solid lawyer: Heads down, hard worker and always ready to solve the next legal issue with precision and ...

India, March 27 -- Daily practice of learning one new word will enhance your language abilities and boost your power to ...

TTP LabTech has announced the results of two collaborative studies using its Acumen eX3 fluorescence microplate cytometer. Collectively, these data demonstrate that the eX3 is a flexible and robust ...